Life Sciences Archive » July, 2019

Life Sciences - July, 2019

348 articles

• Ex-J&J Doctor Testifies She Told Bosses About Mesh Issues
• $17B Or Zilch? Okla., J&J Make Final Pitches After Opioid Trial
• Why Ariz. Is Taking Aim At The Sacklers At The High Court
• True Health Gets Nod For $7.8M DIP After Deadline Shift
• Arbitrator Told To Clarify Trading Firm's $3.6M Award
• J&J Tried To Invade Atty Privilege In Talc Case, Judge Told
• PhRMA's New Attack On Calif. Drug Pricing Law Gets Traction
• Drug Distributor's Ex-CEO Faces May Trial Over Opioid Sales
• Offit Kurman Nabs 4 IP Specialists From Caesar Rivise
• Amarin Asks Justices To Get ITC To Look Into False Ad Claims
• European Venture Outfit Raises $233M For Life Science Fund
• Rosen Law To Lead Indivior Stock Suit Over Opioid Indictment
• Fed. Circ. Upholds PTAB Ax Of Avastin Patent
• Celgene To Pay $62M To End Antitrust Suit Over Cancer Drugs
• Gene Therapy, Drilling Contractor Raise $101.5M In Debuts
• Debunking 3 Myths About Contract Attorneys
• Arizona Files Supreme Court Lawsuit Over Opioid Crisis
• HHS Opens Door To Drug Imports Amid Shaky Pricing Efforts
• J&J 'Would Never Sell' Unsafe Talc, Rep Says In Ky. Trial
• J&J Says FDA, Scientists Found No Asbestos In Baby Powder
• Ex-USPTO Directors, Judges Back Patent Eligibility Overhaul
• Texas Opioid MDL Gets 2020 Trial Dates
• Fed. Circ. Backs Retroactive IPRs, But The Fight Isn't Over
• Pharma Cos. Settle Patent Challenge Over Opioid Treatment
• Diagnostic Firm Says Medicare Holdback Pushed It Into Ch. 11
• Merck, Glenmark Rip Zetia Buyers' Par Deal As 'Tactical Move'
• EEOC Roundup: 7 Things You May Have Missed
• Cancer Biotech Oasmia Hid Deals From Investors, Suit Says
• Mylan Nears $30M Deal In SEC EpiPen Probe; CEO To Retire
• Fed. Circ. Won't Rethink Ruling Invalidating 2 Vimovo Patents
• Ex-Trump Adviser Returns To Baker Donelson Via Alliance
• Vitamin Maker Must Stop Using 'Sugar Bear Hair' Mark
• NJ Appeals Court Revives Homeopathic Flu Remedy Suit
• Wilson Sonsini Nabs Life Sciences, IP Whiz From Jones Day
• The Unique Challenges Of Owning International Cannabis IP
• Patient Drug Guides Vs. The Learned Intermediary Doctrine
• Fate Of CVS-Aetna Deal In The Hands Of Judge
• J&J Lied In Mesh Marketing, Surgeon Tells Calif. Judge
• Hospitals, Insurers Lash Trump's Price-Transparency Demand
• Women Can Drop, Refile Warning Label Suit Over J&J Talc
• Generic Lamictal Buyers Defend Class Cert. At 3rd Circ.
• Pot Dispensary Chain Fires Back Over Ill. License Sale Suit
• Puma Biotech Says Liability Still Unsettled In Stock-Drop Row
• Cancer Patients Breathed In 'Clouds' Of J&J Talc, Jury Told
• CVS To Pay $15M For Unwanted Flu Shot Calls
• Contradiction Ends Amgen's Neulasta IP Suit, Fed. Circ. Says
• 7th Circ. Revives LabCorp Unit Tech's Retaliation Suit
• NY Pharmacist Cops To Role In 'Brazen' $5M Opioid Ring
• Rite Aid Investors Seek Cert. In Failed Walgreens Merger Suit
• Bayer Cornering Market On Pet Tick Meds, Antitrust Suit Says
• Lawmakers Push Bill To Simplify Biosimilar Patent Fights
• Leaked Email In Price-Fixing Case Is Privileged, Heritage Says
• Teva, Endo Curb Pay-For-Delay Pacts In $70M Deal With Calif.
• 'No Miscarriage Of Justice' In Insys Execs' Trial, Feds Say
• 4 Firms Guide Israel-Based Inmode's $75M IPO Pricing
• 3 Firms Lead $2.8B Merger Of Cancer Treatment Developers
• 4 Firms Lead Pfizer Unit's Merger With Mylan
• Law360 Reveals The Global 20 Firms Of 2019
• St. Jude Hit Humana With Faulty Pacemaker Costs, Suit Says
• Meet The Top Attys In Gilead's 'No Generics' Antitrust Rumble
• J&J Unit Urges Philly Judge To Ax Risperdal Damages Trial
• Boston Scientific On Hook For $275M Merger, Chancery Told
• Opioid Seller Seeks To Lead Antitrust Class Despite Charges
• SEC Cuts Deal With Biotech Co. Pump-And-Dump Witness
• AARP Backs Up FTC At 3rd Circ. In AbbVie Antitrust Suit
• Eye Product Co. Says Feds' Attys Breached No-Contact Rule
• Stimwave Appeals Injunction In Spinal Cord Device IP Suit
• Compliance Imperatives For Defensible Data Disposal
• Lawmakers Still Looking For More NAFTA 2.0 Improvements
• AGs Fire Back After Pharma Bid To End Price-Fixing Claims
• First SF Project Under New Plan Gains Approval
• A Litigator's Reflections From The Arbitrator's Chair
• Health Hires: Epstein Becker, Morgan Lewis, Polsinelli
• Monsanto's $2B Roundup Cancer Loss Slashed To $87M
• Colgate, J&J Talc Contained No Asbestos, Geologist Tells Jury
• Florida Wants Redo On Ruling That Gutted Medical Pot Regs
• J&J Takes Aim At Testing Records At NJ Asbestos Talc Trial
• Quick Alice Wins Dwindling In Wake Of Berkheimer Ruling
• Prosthetic Maker Urges FTC To Reverse ALJ Acquisition Block
• PTAB Will Review Hep B Treatment Co.'s Patent
• Pa. Judge Greenlights State's 1st Opioid Marketing Case
• Joerns Gets Nod For $320M Debt-Equity Swap Ch. 11 Plan
• Ill. Marijuana Dispensary Wants Out Of Deal To Sell License
• CMA Accuses Pharmas Of Divvying Market For UTI Treatment
• Memory Booster Maker Can't Forget FTC False Ad Suit
• 5 Hard Phrases Lawyers Should Master
• MilliporeSigma's CRISPR Claims Put Pressure On USPTO
• J&J Digs Into Methods Of Expert Who Found Asbestos In Talc
• Bio-Rad Gets 10X's DNA Products Blocked, Plus $24M Cash
• Document Decision On Hold In J&J Talc Supplier's Ch. 11
• J&J Wasn't Alone In Talc Self-Regulation Push, Jury Hears
• ITC Bans Medical Device Imports That Flout Co.'s Trade Dress
• 3 Young Vapers Sue Juul Over Teen-Targeting Tactics
• Cities, Counties Lose Bid For Committee In Insys Ch. 11 Case
• Celgene To Pay $55M Over Cancer Drug Monopoly Claims
• How Roundup Trials Are Turning Jurors Into Activists
• Allergan Recalls Cancer-Linked Textured Breast Implants
• Impax May Be Trying To 'Game System' In Teva Fight: Judge
• Pfizer Can Pursue Claim For Securities MDL Coverage
• Insights From Recent Cases Considering Waiver Of Privilege
• Heritage Pharma, Former Execs Reach Deal In RICO Suit
• And Now A Word From The Panel: 4 MDL Lessons At 40
• Fed. Circ. Highlights Need For Enabling Disclosure In Patents
• J&J Grills Marketing Expert Who Said It Hid Mesh Risks
• Pelvic Mesh Victim Fights Bid To Seal Malpractice Filings
• Insys GC To Leave Embattled Co. After Less Than A Year
• 3rd Circ. Says Board Observers Not Same As Directors
• J&J Told FDA In '70s Asbestos In Talc Was Safe, Jury Hears
• Big Pharma Pounces On Bipartisan Drug Pricing Bill
• FDA Must Reconsider Denial Of Braeburn Anti-Opioid Drug
• Insys Pulls Support For Novel Gov't Entities Committee
• EpiPen Buyers Target Mylan CEO After Teva Disclosures
• Fed. Circ. Asked To Revive Parts Of Internal-Bleed Device IP
• Investors Clamor To Lead Suit Over Chemical Co. Stock Drop
• Mass. Biotech Co. Liable For CEO Duping Investors, SEC Says
• Nerve Repair Co. Says Stock-Drop Suit Relies On Iffy Sources
• $50M IRS Claim Holds Up Avadel Pharma Ch. 11 Confirmation
• Corcept Wants Sun's Cushing's Syndrome Drug Blocked
• Amgen, Allergan Launch 2 Biosimilars With Court's Blessing
• Calif. Expert Says J&J's 'Propaganda' Misled Mesh Patients
• DOJ Errors Doom Suboxone Film Fraud Case, Indivior Says
• Unlawful Pain Pill Sales Undeniable, Opioid MDL Counties Say
• Test Tube Cancer Research Beats Animal Studies, J&J Hears
• J&J Rep Battles Over Asbestos Definition At NJ Talc Trial
• Omnicell Stock Drop Followed Short Seller's Report, Suit Says
• FTC Asks 3rd Circ. To Revive Claims In AbbVie Antitrust Case
• Purdue Wants Fed. Circ. To Rehear OxyContin Patent Claims
• Strong Debut Augurs Well For China's New Startup Market
• Conn. Denies Leaking Heritage Doc In Generic-Drug Case
• Indian Hospitals Added To Indigenous Opioid Abuse, Feds Say
• Fed. Circ. Denies Stay In High Court-Bound Immunity Case
• Actavis Infringed Constipation Drug Patent, Judge Rules
• Feds Must Hand Over Info In Eye Product Kickback Suit
• Trustee, MDL Group, Maryland AG Blast Insys Ch. 11 Proposal
• ABA Rips USPTO Attorney Fee Rule As 'Radical'
• Books And Records Requests In The Era Of Text Messages
• Covington, Fried Frank Assist On $585M Deal For Dr. Scholl's
• E-Discovery Experts Could Increase Fed. Court Efficiency
• Software Biz Leads 3 Firms In IPO Launches Totaling $546M
• Fed. Circ. Leaves Open Questions On Patent Eligibility
• J&J Still Can't Transfer 2,400 Talc Suits To Del. Fed. Court
• DOJ Tries To Push CVS-Aetna Deal Past Court Review
• Endo Pharma To Pay $2.3M To 18 States In Lidoderm Deal
• Research Refutes J&J Talc Asbestos Claims, Jury Hears
• 'Everybody In The Crosshairs' As DOJ Opioid Blitz Gets Real
• 'Conspiracy' Claim Can't Save Antitrust Case, 7th Circ. Told
• Massachusetts Cases To Watch: Midyear Report
• Goodwin Guides Radiology Biz To $4B Valuation
• 4 Things FTC Competition Bureau Looks For In White Papers
• GSK Calls For Preemption Ruling In Zofran Birth Defect MDL
• Q&A With Skadden Mass Torts Leader John Beisner
• Ex-Merck Workers Get Green Light For $6.2M Sex Bias Deal
• Former Congressman Peter Roskam Joins Sidley Austin
• Preinstitution Submissions May Limit Certain ITC Probes
• Stryker Slams Zimmer's High Court Bid Following $254M Loss
• Talc Left 'Fingerprint' In Ky. Travel Agent's Lungs, Jury Hears
• Pfizer Wants Breast Cancer Drug MDL Consolidated In Del.
• Clark Hill Client Says Firm Pushed $1M Deal For His $63M Suit
• CVS Says It's 'Impossible' To Tell Who's In Price-Gouging Suit
• Pfizer Hid Risks Of Sepsis, Amputation On Labels, Suit Says
• Tax Court Hewed Too Closely To CUT In Medtronic, Atty Says
• Ill. Latest Battleground For Bayer In Essure Safety Suits
• Remembering Justice Stevens As A Law Firm Leader
• 5 Cos. Price IPOs Totaling $1.1B, Led By Danish Biotech Firm
• Texas Firms Aim To Dodge NJ Pelvic Mesh Malpractice Suit
• DOJ Indicts Opioid Distributor, Execs Over Painkiller Sales
• Drugmakers Tell 7th Circ. Insurer's Testosterone Suit Flawed
• A New Era For Human Genetic Resource Compliance In China
• Calif. Privacy Law's 3 Limited Exemptions For Health Cos.
• Martin Shkreli's Conviction Upheld By 2nd Circ.
• Ethicon Mesh Had Abysmal Success Rate, Surgeon Says
• 'May I Just Ask': Era Of Civility Passes With Justice Stevens
• Justice Stevens' Chevron Legacy Under Attack
• Sterigenics Settles Ill. Emissions Suit, Hopes To Reopen Plant
• 'Kindness, Humility, Wisdom': Justices Remember Stevens
• 6th Circ. Tosses Parents' Suit Over Merck's Gardasil
• The Stories They Tell About Justice Stevens
• Hear Justice Stevens In 5 Memorable Moments On The Bench
• 5 Times Justice Stevens Impacted Product Liability Law
• Justice Stevens' High Court Legacy In 4 Charts
• Express Scripts Can't Shake Pa. Records Fee Class Action
• FDA Must Hand Over Theranos Docs To Ex-CEO Holmes
• 4 Key Moments From J&J's Okla. Opioid Trial
• Tiversa Slams LabMD Exec's 'Late' Jury Trial Bid In FCA Suit
• Ariad Exec's Ex Asks 1st Circ. To Nix Insider Trade Conviction
• J&J Talc Supplier Chafes At Insurers' Ch. 11 Doc Demand
• Judge Invaded Jury's Role In Axing J&J Mesh Win, Court Told
• Deals Rumor Mill: Takeda, Dynata, Ferretti
• Loestrin Buyers Win Cert. In Antitrust Battle With Pharmas
• Surgeon Tells Calif. Judge Women's Bodies Reject J&J Mesh
• A Look Back At Justice Stevens' Most Important Opinions
• Justice John Paul Stevens' Brand Of Judicial Humility
• Retired Justice John Paul Stevens, Hero To Left, Dead At 99
• Insurer's Opioid Suit Not Rooted In Federal Law, Judge Says
• FCC Asked To Rescind TCPA Waiver In $925M Robocall Suit
• Records Show J&J Baby Powder Had Asbestos, NJ Jury Told
• Pa. Appeals Court Revives Risperdal Breast Growth Case
• Loestrin Buyers Seek Approval Of $1M Lupin Deal
• What High Court's Kisor Ruling Means For FDA Decisions
• Judge OKs Release Of National Opioid Sales Data
• Answers To Key Legal Finance Ethics Questions
• Preemption Vs. Public Nuisance, In Aviation And Opioids
• Pharmacy Benefit Cos. Improved Opioid Policies, Judge Says
• Former Insys Execs Want Sentencing Delayed Until 2020
• J&J Can't Quit Deception Playbook, Okla. Says In Closings
• Reckitt Hit With Stock Drop Suit Over $1.4B Opioid Probe Deal
• J&J Hid Painful Mesh Problems, Calif. Says At Trial's Start
• Fed. Circ. Backs Nobel Biocare Win In Dental Patent Case
• Impax's Discovery Delay Bid 'Beyond Unreasonable': Judge
• Investor Probing 'Activist' Fund's Role In Pet Firms' Tie-Up
• 4 Mesothelioma Patients Tell NJ Jury J&J Gave Them Cancer
• Philip Morris Looks To Stub Out Suit Over E-Cig Sales, Studies
• J&J Slams 'Gross Mischaracterization' Of Talc Ruling
• Arent Fox Brings FDA Pro Back From McCarter & English
• Pharma Foes Both Want Wins In Drug Access Antitrust Suit
• Federal Agencies Need A Uniform Record-Keeping Process
• E-Prescription Co. Hopes To Zap FTC Monopoly Case
• Insys Proposes Novel Gov't Committee Deal In Ch. 11 Case
• Investors Say Sales Potential Of Hair Transplant Robot Inflated
• Breaking Down J&J And California's $1B Pelvic Mesh Trial
• Avon Nears Costs Win After Cancer Victim Rejects $10K Deal
• J&J Again Asks For Win As Okla. Opioid Trial Testimony Ends
• How A Doc's FCA Suit Turned Into $1.4B Opioid Deal
• Fed. Circ. Largely Backs Generics In Suboxone Patent Fight
• Fla. Jury Absolves Zimmer In Hip Implant Injury Suit
• SEC Accuses 'Experienced' Securities Atty Of Trading Scheme
• Native American Cases To Watch In 2nd Half Of 2019
• No Summer Break Yet As 10 Firms Ready 9 IPOs For Market
• FDA Ordered To Impose 10-Month Deadline For E-Cig Apps
• Deals Rumor Mill: NSF, Clariant, Armacell
• Weak Ties To Imerys Ch. 11 Get J&J Talc Suit Remanded
• Merck Says Zetia Buyers Can't Expand Pay-For-Delay Suit
• L'Oreal Dodges Claims Over Misleading Cosmetics Bottles
• J&J Surgical Staplers Injured Man's Stomach, Suit Claims
• The Role Of Dictionaries In Last Term's High Court Decisions
• How To Evaluate The Rise In Legal Employment
• Tips For Patenting And Protecting Wearable Technology
• Allergan's Bid To Block Imprimis Drug Sales Limited To Calif.
• J&J Opioids Were Sliver Of The Okla. Market, Judge Told
• Fed. Circ. Unsure If PTAB Has To Explain Axing Avastin Patent
• Reed Smith Atty's Widow Fails To Reclaim $3M Win Over GSK
• Insurers Want To Investigate J&J Talc Supplier's Ch. 11
• Loestrin Buyers Fight To Advance Antitrust Case To Trial
• Prosthetic Maker Can't Save Acquisition, FTC Staffers Say
• Couple Sues Fertility Center For Implanting Wrong Embryos
• Deals Rumor Mill: J.Crew, AB InBev, Hitachi
• Abiomed Exec Should Get Paid Despite Firing, 1st Circ. Told
• IPO Surge Produces Record Exits For Venture Capital
• Eli Lilly Searches For New GC As Top Atty Plans To Retire
• Gilead Seeks To Nix Patients' Suit Over HIV Drug Toxicity
• Indiana AG Says Medical Debt Collector Belongs In Ch. 7
• Foreign Investment In US Biotech Gets Greater Gov't Scrutiny
• Cleary Guides Agilent's $1.17B Deal For BioTek Instruments
• Biosimilar Patent Litigation Bill Would Change BPCIA Strategy
• Reckitt To Pay $1.4B To End US Opioid Probe
• Opioid Crisis Not Ex-J&J Subsidiary's Fault, Exec Testifies
• Fed. Circ. Agrees Prenatal DNA Test Patent Doesn't Hold Up
• Fed. Circ. Pleads For Patent Eligibility Clarity: What Now?
• Ex-Illumina Accountant Traded Tips For NYC Trip, SEC Says
• New Trial Upheld For J&J After $417M Talc Verdict
• Trump Sizing Up India As New Trade Nemesis
• The Top Deals Of The First Half And The Firms That Led Them
• EU Clears GSK-Pfizer Joint Venture With Conditions
• Rival Can't Challenge Verdict Over Contract, Drug Co. Says
• Heritage Says Conn. Leaked Email About Congressional Probe
• Disciplinary Action Omission Prompts Atty Admission Redo
• Insys May Face Restitution Above $30M Penalty For Kickbacks
• GSK Gets 2nd Chance To Argue Preemption In Zofran MDL
• Investors' $1.95M Deal Over Merger Disclosures Gets OK
• 3 Takeaways From Nixing Of Drug Pricing Rule
• Cozen O'Connor DQ'd Over Client Conflict In Cannabis Deal
• Kirkland, Jones Day Guide $170M PE Deal For Aspen Surgical
• 3M Says Patient Attys' Sanctions Bid Over Docs Retaliatory
• Bio-Rad's $24M DNA Patent Win Backed By Evidence: Judge
• Okla. Says J&J Addiction Expert Is Just A 'Book Reviewer'
• Fla. Medical Marijuana Statute Deemed Unconstitutional
• BioScrip Investor Wants Option Care Merger Vote Halted
• The Business Case For Championing Diverse Legal Teams
• Deals Rumor Mill: Generali, WPP, Bayer
• Freshfields Guides Biotech Co. In $325M Funding Round
• Can Data Solve BigLaw's Diversity Problems?
• 12 Attorneys On How Diversity Gives Them The Edge
• Pa. Justices Urged To OK Experts In Pesticide Cancer Case
• Ex-CCO Says She Was Fired For Blowing Whistle On Boss
• Streaming Co. Leads 4 IPO Launches Set To Raise Over $1.8B
• Nursing Home Operator Owes $2M To Brain Clinic: 7th Circ.
• GSK Says Reed Smith Widow Can't Ignore 'Final Judgment'
• 3rd Circ. Suggests Remicade Fight May Require Arbitration
• What A Maturing Patent Bar Means For The Industry
• J&J Loses Bid To Escape Okla.'s Opioid Megatrial
• Sanofi, Eisai Back Lilly's $20M Cialis Patent Loss Challenge
• How The Legal Pipeline Is Failing Black Attorneys
• Judge Nixes Rule Forcing Drug Prices In TV Ads
• In Their Own Words: 9 Partners On Diversity At Work
• Ex-Atty, Informant Gets 1½ Years In $3.9M Trading Scheme
• The Best Firms For Minority Equity Partners
• Ex-Insys Bosses Still Aiding 8 Kickback Probes, Feds Say
• 3 Health Care-Focused Cos. Launch IPOs Totaling $277M
• The Art Of The 'Science And Expert Team' In Mass Torts
• Biggest Merger Reviews Of 2019: Midyear Report
• Akorn Investors Seek Cert. In Suit Over Failed Merger
• Cannabis-Related Patent, TM Filings Increase After Farm Bill
• Roche, Spark Extend Deadline For $4.8B Takeover Offer
• Misconceptions In The Debate About Noncompetes
• Diversity Efforts At Many Firms Ignore Disabled Attorneys
• Law360's Diversity Snapshot By The Numbers
• Despite Progress, Firms Still Slow To Track LGBT Data
• The Best Firms For Minority Attorneys
• J&J Cash Can't Sway Medicine's High Priests, Surgeon Says
• Product Liability Cases To Watch: Midyear Review
• Fractured Full Fed. Circ. Won't Eye Patent Eligibility Rules
• Okla. Opioid Case 'Should End Here And Now,' J&J Says
• J&J's Kirkland Attys Are Rehashing Old Fights, Judge Told
• Novum Pharma Seeks $3M Ch. 11 Loan To Fund Restructuring
• Latin American Energy Co., Biotech Firm Join IPO Pipeline
• AbbVie's $16.7M Inversion Settlement Gets Initial Approval
• Health Hires: Carlson & Jayakumar, Baker Donelson, Ropes
• 9th Circ. Seeks Nevada's Help With Defense Recoup Riddle
• The Top Antitrust Conduct Cases Of 2019: Midyear Report
• J&J Opioid Sales Rep Wooed 'Pill Mill' Doctors, Judge Hears
• 'Extraordinary' $100M Fraud Gets Ex-Pharma CEO 30 Years
• Supreme Court IP Recap: Patents
• Wilson Sonsini Blasts Zetia Buyers' Bid For More Docs
• Feds, Drugmakers Grilled Over Rule Mandating Prices In Ads
• 2 Firms Grab Spotlight In Scorching June For IPOs
• Cooley Hid Conflict While Helping Launch Company, Suit Says
• Insys Reaches Ch. 11 Deal To Pause State Opioid Suits
• NYC Doc Convicted In $2M Opioid Scheme Gets 5 Years
• 2 Firms Seek Lead In Investor Suits Over GTx-Oncternal Deal
• Antares Pharma Escapes Fraud Suit Over Drug Statements
• Sidley Helps Varian Ink $90M Deal To Bolster Cancer Portfolio
• Rethinking The Tech-First Approach To Law Firm Solutions
• Limits Of DOJ's Qui Tam Dismissal Authority Are Unsettled
• ITC To Investigate Intuitive Surgical's Cartridge Imports
• At Sentencing, Ex-CEO Argues $100M Fraud Didn't Sink Bank
• J&J's Addiction Expert Slammed For Touting Screening Tools
• Drug Return Co. Must Pay $94M Restitution In Fraud Case
• Sanofi Casting Blame For Failed EpiPen Rival, Mylan Says
• Pharmacy, PE Fund Near Deal To End Feds' FCA Kickback Suit
• Opioid MDL Litigants Seek Triumphs Before Bellwether Trial
• Finnegan Leveraged Vagisil's Fame To Block Rival's TM
• Valeant Investor Can't Duck Insider Trading Claims
• Biopharm Co. Gets Rare Jump On $17.4M Ch. 11 Asset Sales
• Haynes And Boone Snags 2 IP Partners From Brinks Gilson
• TWi Must Pay Fees After Ignoring Court Warnings In IP Row
• J&J Investors Fight To Keep Asbestos Stock-Drop Suit Alive
• How Opioid 'Negotiating Class' Would Affect Civil Claims
• BPI Supplement Doesn't Build Muscle As Promised, Suit Says